BioSensics
BioSensics develops FDA-listed wearable sensors and digital health platforms for clinical trials in neurological, neuromuscular, and rare disorders. It serves pharmaceutical companies, biotech firms, academic medical centers, and CROs across 30+ countries, with 100+ trials and 200+ publications validating its digital biomarker technologies.
- Company typePrivate
- Founded2007
- HeadquartersWatertown, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioSensics does
BioSensics LLC is a privately held medical device and digital health company founded in 2007 by three Harvard University scientists and headquartered in Newton, Massachusetts. The company develops FDA-listed Class II wearable sensors, including the PAMSys family (PAMSys, PAMSys ULM, PAMSys Voice, PAMSys Fall, PAMSys Gait), LEGSys, BalanSens, and BioDigit Watch, combined with a suite of digital health platforms (BioDigit Home, BioDigit Clinic, BioDigit Speech, BioDigit Video) and a curated digital biomarker database (BioDigit Database). Its technology stack covers 3D accelerometry, IMU, audio capture, and proprietary algorithms for motion, speech, postural, gait, balance, and cognitive analysis, with ISO 13485, CE mark under MDR 2017/745, HIPAA, GDPR, and Data Privacy Framework compliance.
The company focuses on neurological, neuromuscular, autoimmune, and rare disorder indications including Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, multiple system atrophy, myasthenia gravis, hereditary ataxias, and progressive supranuclear palsy. Customers include pharmaceutical and biotech companies (25+ on BioDigit Home), academic medical centers (MGH, Johns Hopkins, Vanderbilt, Baylor, Spaulding, Beth Israel Deaconess, University of Rochester, Penn State, Kansas University), CROs, and patient advocacy organizations. Its technologies have been deployed in 100+ clinical trials and research studies across 30+ countries and 20+ languages, with 25+ trials using BioSensics products as primary or secondary endpoints and 200+ peer-reviewed publications generated from the installed base.
BioSensics monetizes through three revenue streams: hardware sales of FDA-listed wearable devices, subscription/licensing of BioDigit software platforms and database access, and professional services for clinical trial operations including study management, data quality monitoring, and technical consulting. Distribution is direct enterprise sales supported by conference-driven demand generation (AAN, MDA, DIA, CTAD, CNS Summit). R&D is heavily funded through NIH grants (over $50M cumulatively across NIA, NICHD, and other institutes), with partnerships spanning pharma (Alterity, Elpida), academic KOLs, advocacy groups (MDA, ALSA, CurePSP, AFTD, HNF, MGFA, FARA), and consortia (Digital Medicine Society).
BioSensics firmographics
Firmographics- Name
- BioSensics
- Legal name
- BioSensics LLC
- Website
- https://biosensics.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioSensics develops FDA-listed wearable sensors and digital health platforms for clinical trials in neurological, neuromuscular, and rare disorders. It serves pharmaceutical companies, biotech firms, academic medical centers, and CROs across 30+ countries, with 100+ trials and 200+ publications validating its digital biomarker technologies.
- Ownership category
- akta.pro rank
BioSensics industry classification
Industry- Product category
- Wearable Medical Devices and Digital Health Platforms
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where BioSensics is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioSensics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Wearable Sensor Hardware Sales: Sale of FDA-listed wearable devices including PAMSys, LEGSys, BalanSens, PAMSys ULM, and BioDigit Watch. Devices are sold as Class II medical devices with FDA listing and CE mark for use in global clinical trials.
- Digital Health Platforms and Software: Subscription and licensing of software platforms including BioDigit Home, BioDigit Speech, BioDigit Video, and BioDigit Database for data collection, analysis, and storage.
- Clinical Trial Services: Comprehensive technical and operational services for clinical trials including study management, data quality monitoring, technical/scientific consulting, and early phase study collaboration. Services include device logistics, site training, data management, and regulatory guidance.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
BioSensics product offering
Product offeringCore offering
BioSensics develops and sells FDA-listed Class II wearable medical devices (PAMSys, LEGSys, BalanSens, PAMSys ULM, PAMSys Voice, BioDigit Watch) and integrated digital health software platforms (BioDigit Home, BioDigit Clinic, BioDigit Speech, BioDigit Video, BioDigit Database) for objective measurement of motor, speech, cognitive, and behavioral symptoms in clinical trials and remote patient monitoring. The company also provides clinical trial operational and scientific services, including study management, data quality monitoring, and technical consulting. Its offerings are targeted at pharmaceutical and biotech companies, academic medical centers, and CROs conducting research in neurological, neuromuscular, autoimmune, and rare disorders.
Product overview
BioSensics is a platform-plus-modules company offering end-to-end digital health solutions for clinical trials, patient monitoring, and health assessment. The core offering is built around PAMSys wearable sensors (FDA-listed Class II medical devices for continuous physical activity monitoring) combined with BioDigit digital health platforms. BioDigit Home serves as the unified remote monitoring platform integrating data from PAMSys and PAMSys ULM (upper limb monitoring), PAMSys Voice (speech monitoring), BioDigit Speech, BioDigit Video, and ePROs. The BioDigit Database provides disease-specific digital biomarker data for research access. LEGSys and BalanSens are FDA-listed gait and balance assessment devices. BioSensics also offers clinical services including study management, data quality monitoring, and technical/scientific consulting.
Differentiator
Problem solved
Functional benefit
Brands
- PAMSys: FDA-listed wearable sensor for continuous monitoring of body postures, postural transitions, and walking parameters during activities of daily living
- LEGSys
- BalanSens
- BioDigit Watch
- BioDigit Speech
- BioDigit Video
- BioDigit Home
- BioDigit Clinic
- BioDigit Database
- Nili
- StrokeWear
- PAMSys ULM
- PAMSys Voice
Products and services
- PAMSys FDA-listed Class II wearable sensor for continuous monitoring of body postures, postural transitions, and walking parameters during activities of daily living. Measures 27 independent parameters of daily physical activity including walking/running parameters, body posture, postural transitions, activity levels, sleep quality, and fall detection. Up to 6 weeks battery life with wireless charging support. Used in clinical trials and remote patient monitoring.
- LEGSys FDA-listed wearable sensor system for clinical gait and balance assessments. Used in 200+ clinical studies and trials including measurement of primary endpoints in 15+ clinical trials.
- BalanSens FDA-listed wearable device for clinical balance assessments. Part of the first FDA-listed wearable devices for instrumented gait and balance assessments released in 2013.
- PAMSys ULM (Upper Limb Monitoring) Pioneering wearable sensor for continuous monitoring of upper limb health and function during everyday activities. Uses clinically validated models for goal-directed movements with hand trajectories toward specific target locations. Applied in studies for ALS, Friedreich's ataxia, myasthenia gravis, congenital myasthenic syndrome, stroke, Huntington's disease, and inclusion body myositis.
- PAMSys Voice
Quantifiable outcome
- 100+ clinical trials and research studies conducted with BioSensics technology
- +4 more outcomes
Companies that use BioSensics
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
BioSensics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature10 records
BioSensics partnerships and signals
Strategic signalPartnerships
21 partnerships are on record, tiered core and minor.
- Elpida TherapeuticscorePartnership to advance rare disease clinical trials combining Elpida's gene therapy expertise with BioSensics' advanced digital health platforms and wearable sensor technologies to improve trial accuracy and enhance patient experience.
- Baylor College of MedicinecoreCollaboration on Nili care coordination platform for dementia care and digital biomarker research. Multiple NIH-funded projects including PAMSys Voice development and ADRD care management platform.
- Massachusetts General HospitalcoreMultiple collaborations including ALS digital biomarker study, myasthenia gravis pilot study (BioDigit MG), PSP longitudinal study, and FTLD syndromes research. Includes Dr. Amanda Guidon, Dr. Anne-Marie Wills.
- Johns Hopkins School of MedicinecoreCollaboration on FTLD syndromes research including remote monitoring solutions for PSP with Dr. Alex Pantelyat, Director of Atypical Parkinsonism Center.
- Vanderbilt University Medical CentercoreCollaboration on wearable sensors for quantitative motor assessments in multiple system atrophy with Dr. Daniel Claassen.
- Spaulding Rehabilitation HospitalcoreCollaboration on PAMSys ULM development for upper limb monitoring and StrokeWear device for stroke rehabilitation with Dr. Paolo Bonato, Director of Motion Analysis Laboratory.
- University of RochesterminorResearch partner institution listed on company partnerships page.
- Penn State College of MedicineminorCollaboration on multi-modal remote monitoring of ALS using wearable sensors and digital assessments.
- Kansas University Medical CenterminorResearch partner institution listed on company partnerships page.
- Beth Israel Deaconess Medical CenterminorResearch partner institution listed on company partnerships page.
- Digital Medicine Society (DiMe)corePartnership in Digital Measures Development ADRD project to expedite progress of Alzheimer's disease and related dementias research. Leverages BioDigit Database to facilitate recognition of digital biomarkers for clinical trials.
- Hereditary Neuropathy Foundation (HNF)coreCo-sponsor of wearable-based monitoring study for Charcot-Marie-Tooth disease actively enrolling pediatric participants ages 8-18 at HNF CMT Summit.
- MDA (Muscular Dystrophy Association)corePatient advocacy group partner for muscular dystrophy research including MDA Clinical & Scientific Conference sponsorship.
- CurePSPcorePartnership with CurePSP Center of Care at Massachusetts General Hospital for progressive supranuclear palsy research.
- FARA (Friedreich's Ataxia Research Alliance)minorPatient advocacy group partner for Friedreich's ataxia research.
- ALSA (ALS Association)minorPatient advocacy group partner for ALS research.
- AFTD (Association for Frontotemporal Degeneration)minorPatient advocacy group partner for frontotemporal degeneration research.
- MGFA (Myasthenia Gravis Foundation of America)minorPatient advocacy group partner for myasthenia gravis research.
- National Institute on Aging (NIA)coreNIH institute providing grant funding for Alzheimer's disease and related dementias research including Nili platform development (~$3M grant R44AG066360) and recognition as leading digital health technology provider.
- NICHD (Eunice Kennedy Shriver National Institute of Child Health and Human Development)coreNIH institute providing $3M grant for StrokeWear device development for stroke rehabilitation in collaboration with Spaulding Rehabilitation Hospital.
- Alterity TherapeuticsminorCollaboration on use of PAMSys as secondary endpoint in Phase 2 trial in Multiple System Atrophy.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
BioSensics competitors and assessment
Company assessmentDirect peers
- ActiGraph: ActiGraph is a leading provider of wearable activity monitors (CentrePoint series) used in clinical trials and academic research, competing directly with BioSensics' PAMSys in physical activity, sleep, and actigraphy endpoints for pharma-sponsored studies.
- VivoSense: VivoSense develops wearable sensor analytics and digital biomarkers for clinical trials, with a focus on regulatory-grade endpoints in neurological, respiratory, and rare disease indications - directly comparable to BioSensics' BioDigit platform.
- Empatica: Empatica makes FDA-cleared wearable sensors (EpiMonitor, Embrace) for seizure detection and clinical research, with overlapping pharma clinical trial use cases and similar wearable-plus-algorithm digital biomarker positioning.
- Koneksa Health: Koneksa Health provides digital biomarker solutions for clinical trials using wearable sensors and remote assessments in respiratory, CNS, and rare disease indications, with a similar pharma/biotech customer base and decentralized trial focus.
Emerging players
- Aparito: Aparito develops wearable and video-based digital endpoints for rare disease and oncology clinical trials, overlapping BioSensics' neurological/rare disease focus but with a narrower therapeutic footprint and emerging commercial scale.
- Science 37: Science 37 operates a decentralized clinical trial operating system that integrates remote data capture and connected devices for pharma sponsors, complementary and partially competitive with BioSensics' BioDigit Home trial platform.
Broad incumbents
- Clario: Clario (formed via ERT/BIOPRO merger) is a leading clinical trial endpoint technology provider offering wearable sensors, eCOA, imaging, and cardiac safety - a much broader incumbent that competes with BioSensics in wearable clinical trial endpoints.
- Medidata (Dassault Systèmes): Medidata offers the Rave Clinical Cloud including eCOA, EDC, and an expanding sensor/wearable integration layer for decentralized trials, competing with BioSensics' BioDigit Home platform as part of a much wider clinical trial technology suite.
- Verily (Alphabet): Verily develops wearable sensors (Verily Study Watch) and digital biomarker platforms for large-scale clinical research and pharma trials, with overlapping pursuits in objective, continuous endpoints but as part of a much broader Alphabet-backed portfolio.
- Philips: Philips provides remote patient monitoring and clinical trial wearables/biomarker solutions through its Connected Care segment, competing with BioSensics in RPM and clinical-grade sensor deployments across hospital and pharma customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
BioSensics social profiles
Digital presenceBioSensics compliance and trust
Trust signalCompliance6 records
BioSensics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioSensics leadership team
Management profileNumber of profiles
Profiles1 record
BioSensics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioSensics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioSensics
What does BioSensics do?
BioSensics develops and sells FDA-listed Class II wearable medical devices (PAMSys, LEGSys, BalanSens, PAMSys ULM, PAMSys Voice, BioDigit Watch) and integrated digital health software platforms (BioDigit Home, BioDigit Clinic, BioDigit Speech, BioDigit Video, BioDigit Database) for objective measurement of motor, speech, cognitive, and behavioral symptoms in clinical trials and remote patient monitoring. The company also provides clinical trial operational and scientific services, including study management, data quality monitoring, and technical consulting. Its offerings are targeted at pharmaceutical and biotech companies, academic medical centers, and CROs conducting research in neurological, neuromuscular, autoimmune, and rare disorders.
Is BioSensics a public or private company?
BioSensics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioSensics founded?
BioSensics was founded in 2007. It employs 11 to 50 people.
Where is BioSensics based?
BioSensics is headquartered in Watertown, United States, in the North America region.
How does BioSensics make money?
Three revenue lines are on record. Wearable Sensor Hardware Sales are the primary driver. The others are digital Health Platforms and Software and clinical Trial Services.
Who are BioSensics's main competitors?
Direct peers on record are ActiGraph, VivoSense, Empatica and Koneksa Health. Emerging players are Aparito and Science 37. Broad incumbents are Clario, Medidata (Dassault Systèmes), Verily (Alphabet) and Philips.
Does BioSensics have an API?
No public API is recorded for BioSensics.
What industry is BioSensics in?
BioSensics's product category is Wearable Medical Devices and Digital Health Platforms. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 3391 and its SIC code is 3841.